Insider trade

Neuropace (NPCE): Director bought ~$104K

R Scott Huennekens, Director at Neuropace, bought ~$104K of Neuropace shares.

~$104K
Approx. value · 13K sh @ $8.29
13K
Holds after · shares reported
Traded
Nov 18, 2026
Filed
Nov 18, 2026

What stands out in this filing

  • 3 NPCE insiders bought within the same week. That happened once before in filings since 2021: Apr 2021.
  • R Scott Huennekens's first open-market purchase of NPCE in filings since 2021.
  • After this purchase the filing reports 12,500 shares, held indirectly.
  • 12,500 shares at an average of $8.29 each, as reported on the form.
  • 2 other insiders at NPCE also bought in the open market within 30 days.
  • NPCE closed at $8.22 on Nov 18, 2026, 9% above its 52-week low and 57% below its high, after a 36% drop over the previous 30 trading days.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade. A share price line is a session where the close moved at least 10% and four times its usual daily change.

The company's last weighty Form 8-K report up to this date: reported its results, 6 days earlier (Nov 12, 2026).

  1. Federal contract · $37K obligatedDepartment of Veterans Affairs awarded NeuroPace Inc: $37K obligated to date
  2. Company filing · Form 8-K · ResultsReported its results
  3. Share price · 12.02 → 7.56, about 16× a usual dayShare price fell 37.1% in one session
  4. Insider · 2 peopleInsiders: 2 purchases (~$198K)
  5. Insider · 3 insiders in a week, 2nd time since 2021Director purchased ~$104K of NPCE shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Neuropace

For Neuropace, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NPCE page.

How this filing works

Explore the data

Common questions

Which Neuropace (NPCE) insider traded, and how much?

R Scott Huennekens, Director at Neuropace, bought ~$104K of Neuropace shares. 13K shares at $8.29, open market.

When did it happen, and when was it made public?

Traded: Nov 18, 2026. Filed: Nov 18, 2026.

What stands out in this filing?

3 NPCE insiders bought within the same week. That happened once before in filings since 2021: Apr 2021. R Scott Huennekens's first open-market purchase of NPCE in filings since 2021. After this purchase the filing reports 12,500 shares, held indirectly.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Neuropace recently?

For Neuropace, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 federal contract award dated in the last 90 days. They are listed on the NPCE page.

Does this mean NPCE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Neuropace

Everything OQRO holds on this company is on its NPCE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data